Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidoglycan is an essential polymer that forms a mesh-like layer outside the plasma membrane of most bacteria, providing structural strength and protection against osmotic lysis (PubMed, PMID: 18476318). The D-alanyl-D-alanine (D-Ala-D-Ala) terminus is a critical structural motif found on the peptide stems of peptidoglycan precursors, such as Lipid II, and nascent peptidoglycan chains in Gram-positive bacteria (StatPearls, NBK459358). Glycopeptide antibiotics, including vancomycin and teicoplanin, target this motif by forming hydrogen bonds with the D-Ala-D-Ala dipeptide, which sterically inhibits the transpeptidation and transglycosylation steps of cell wall synthesis (PubMed, PMID: 11084357). The pentaglycine bridge is a specific interpeptide cross-link, most notably found in Staphylococcus aureus, that connects the L-lysine of one peptide stem to the D-alanine of another (PubMed, PMID: 1489457). This bridge is the primary target for the bacteriolytic enzyme lysostaphin, which cleaves the glycine-glycine bonds within the bridge to cause rapid cell wall degradation (PubMed, PMID: 15105404). Because these structures are unique to bacteria and absent in human cells, they represent highly selective targets for antimicrobial therapy. However, the emergence of resistance, such as the modification of D-Ala-D-Ala to D-Ala-D-Lac, poses a significant challenge to the continued efficacy of drugs targeting these sites (PubMed, PMID: 10601204). These targets are primarily relevant in the treatment of severe infections caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).
Glycopeptide antibiotics bind to the D-Ala-D-Ala terminus to inhibit transpeptidation and transglycosylation, while enzymes like lysostaphin cleave the pentaglycine bridge to cause bacterial lysis.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidoglycan D-alanyl-D-alanine terminus and pentaglycine cross-link (D-Ala-D-Ala/Pentaglycine).